Cases

DYK, Circuit Judge. The Medicines Company (“Medicines”) is the owner of U.S. Patent Nos. 7,582,727 (“the ’727 patent”) and 7,598,343 (“the ’343 patent”). In response to an Abbreviated New Drug Application (“ANDA”) submitted by Mylan, Inc. (“Mylan”), Medicines filed suit in the United States District Court for the Northern District of Illinois alleging that Mylan’s ANDA infringed

MEMORANDUM OPINION AND ORDER AMY J. ST. EVE, District Court Judge: In this patent infringement action, The Medicines Company (“TMC”) asserts that Defendants’ proposed generic bivalirudin drug product infringes United States Patent No. 7,582,727 (the “’727 patent”). Specifically, TMC claims that Defendants Mylan, Inc., Mylan Pharmaceuticals Inc. and Bioniche Pharma USA, LLC (collectively, “Mylan

MEMORANDUM OPINION AND ORDER AMY J. ST. EVE, District Court Judge: Defendants Mylan Inc., Mylan Pharmaceuticals Inc., and Bioniche Pharma USA, LLC (collectively, “Defendants”) have moved to amend the Court’s Amended Final Judgment in light of the United States Court of Appeals for the Federal Circuit’s recent opinion in this case. (R. 676.) Plaintiff The Medicines Company (“TMC”) opposes Defendants’ mo

REDACTED MEMORANDUM OPINION AND ORDER AMY J. ST. EVE, District Judge. Before the Court is Defendants’ motion to compel testimony and production of information withheld on the basis of privilege by Plaintiff pursuant to Federal Rule of Civil Procedure (“Rule”) 37(a). (R. 184, Mot. to Compel.) Specifically, Defendants seek production of (1) privileged and non-privileged- documents and items' in Pl

Hughes, Circuit Judge. The Medicines Company appeals findings of no infringement made by the United States District Court for the District of Delaware. Hospira cross-appeals the district court’s finding that a distribution agreement did not constitute an invalidating “offer for sale” under 35 U.S.C. § 102(b). We affirm the district court’s noninfringeme

ANDREWS, U.S. DISTRICT JUDGE Plaintiffs brought separate patent infringement actions against Mylan Technologies Inc., Mylan Pharmaceuticals Inc., and Mylan N.V., and Alvogen Pine Brook Inc., in 2015. (No. 15-0477-RGA, D.I. 1, D.I. 48; No. 15-1016-RGA, D.I. 1, D.I. 66).1 The two cases were consolidated. (D.I. 140). On September 26, 2017, Plaintiffs and the Mylan Defendants entered into a Settlement Agree

PRECEDENTIAL UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT _______________ Nos. 22-1193, 21-1194 and 22-1195 _______________ MYLAN INC & SUBSIDIARIES v. COMMISSIONER OF INTERNAL REVENUE, Appellant _______________ On Appeal from the United States Tax Court (IRS-1: 16-26976, 16-26977 and 16-26978) Tax Court

PROST, Chief Judge. Eli Lilly & Co. (“Eli Lilly”) is the owner of U.S. Patent No. 7,772,209 (“ ’209 patent”). It fried this consolidated Hatch-Wax-man suit against Teva Parenteral Medicines, Inc.; APP Pharmaceuticals LLC; Pliva Hrvatska D.O.O.; Teva Pharmaceuticals USA, Inc.; and Barr Laboratories, Inc. (collectively, “Defendants”) to prevent Defendants from launching a ge

MEMORANDUM GREGORY M. SLEET, UNITED STATES DISTRICT JUDGE I. INTRODUCTION In this patent infringement action, plaintiffs Pfizer Inc., Pharmacia & Upjohn Company, Pharmacia & Upjohn Company LLC, Sugen, Inc., C.P. Pharmaceuticals International C.V., Pfizer Pharmaceuticals LLC, and PF Prism C.V. (collectively, “Pfizer”) allege that pharmaceutical products proposed by de

Concurring opinion filed by Circuit Judge Dyk. Moore, Circuit Judge. *1325Mylan Pharmaceuticals, Inc., petitioned for inter partes review ("IPR") of various patents owned by Allergan, Inc., relating to its dry eye treatment Restasis. Teva Pharmaceuticals USA, Inc., and Akorn, Inc. (together with Mylan, "Appellees") joined.

Opinion for the court filed by Circuit Judge TARANTO. Opinion concurring in the judgment filed by Circuit Judge O’MALLEY. TARANTO, Circuit Judge. ■ These appeals involve two actions brought in the District of Delaware against generic drug manufacturer Mylan Pharmaceuticals Inc. One, assigned to Chief Judge Stark, was brought by brand-name drug manufacturers Acorda Therapeutics Inc. and Alkermes Pharma Irelan

Lourie, Circuit Judge. *1368 Mylan Pharmaceuticals Inc. ("Mylan"), Breckenridge Pharmaceutical, Inc. ("Breckenridge"), and Alembic Pharmaceuticals, Ltd. ("Alembic") (collectively, "Appellants") appeal from the final written decision of the U.S. Patent and Trademark Office Patent Trial a

Mylan Technologies, Inc. v. Zydus Noveltech, Inc., No. S0041-09 CnC (Crawford, J., Dec. 21, 2012) [The text of this Vermont trial court opinion is unofficial. It has been reformatted from the original. The accuracy of the text and the accompanying data included in the Vermont trial court opinion database is not guaranteed.] STATE OF VERMONT SUPERIOR COURT

*656 FINDINGS OF FACT AND CONCLUSIONS OF LAW GRANTING JUDGMENT IN FAVOR OF THE PLAINTIFFS, DEY L.P. AND DEY, INC. ’ IRENE M. KEELEY, District Judge. I. INTRODUCTION The plaintiffs, Dey, L.P. and Dey Inc. (collectively “Dey”), have asserted eight causes of action against the defendants, Teva Parenteral Medicines,

OPINION SUE L. ROBINSON, District Judge. I. INTRODUCTION This action arises out of the filing of Abbreviated New Drug Applications (“ANDAs”) by Mylan Pharmaceuticals Inc. (“Mylan”) and Teva Pharmaceuticals USA, Inc. (“Teva”) seeking to market generic versions of Tarceva® (eriotinib tablets), used to treat certain indications of non-small cell lung cancer and pancreatic cancer. Plaintiff OS

696 F.Supp.2d 599 (2010) Tara VITATOE, individually and as next friend and natural mother of Jacobie Vitatoe, a minor, Plaintiff, v. MYLAN PHARMACEUTICALS, INC., Mylan, Inc., and Mylan Laboratories, Inc., Defendants. Civil Action No. 1:08CV85. United States District Court, N.D. West Virginia. March 5, 2010. *602 Cyndi M. Rusnak,

Appellate Case: 21-3005 Document: 010110717852 Date Filed: 07/29/2022 Page: 1 FILED United States Court of Appeals PUBLISH Tenth Circuit UNITED STATES COURT OF APPEALS July 29, 2022

15 So.3d 642 (2009) ABBOTT LABORATORIES, Appellant, v. MYLAN PHARMACEUTICALS, INC., Appellee. No. 1D08-0602. District Court of Appeal of Florida, First District. June 22, 2009. *644 Michael J. Glazer and John R. Beranek of Ausley & McMullen, Tallahassee, for Appellant. William E. Williams and Amy W. Schrader of GrayRob

670 F.Supp.2d 359 (2009) DAIICHI SANKYO COMPANY, LIMITED and Daiichi Sankyo, Inc., Plaintiffs and Counterclaim Defendants, v. MYLAN PHARMACEUTICals inc., Mylan Laboratories Inc., Matrix Laboratories, Ltd., and Mylan, Inc., Defendants and Counterclaim Plaintiffs. Civ. Nos. 06-3462, 07-3039, 08-2752. United States District Court, D. New Jersey. July 30, 2009.

Opinion & Order BARBARA S. JONES, District Judge. *387TABLE OF CONTENTS INTRODUCTION. CO CO o I. The Parties. CO CO o II. The Patents-In-Suit. 03 05 CO A. Patent Ownership. CO CO III. The Pleadings. CO CO A. Complaint Against Mylan/Esteve.